Caricamento...
A Chaperone Enhances Blood α-Glucosidase Activity in Pompe Disease Patients Treated With Enzyme Replacement Therapy
Enzyme replacement therapy is currently the only approved treatment for Pompe disease, due to acid α-glucosidase deficiency. Clinical efficacy of this approach is variable, and more effective therapies are needed. We showed in preclinical studies that chaperones stabilize the recombinant enzyme used...
Salvato in:
Pubblicato in: | Mol Ther |
---|---|
Autori principali: | , , , , , , , , , , , , , , , , , , , , , |
Natura: | Artigo |
Lingua: | Inglês |
Pubblicazione: |
Nature Publishing Group
2014
|
Soggetti: | |
Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4429731/ https://ncbi.nlm.nih.gov/pubmed/25052852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.138 |
Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|